God  our Guide  

CIDP info
Diet anti-inflammatory
Burning  Feet Home
Services Page
Chronic Fatigue
Autoimmune diseases
Bible healing
Celiac disease
 Hearing Loss

B-12 deficiency

Cancer therapy

cancer treatment almonds

Bulemia TMS Thearapy

B-17 cancer

Silver Filling

Cancer Clinic

Cancer & Flaxseed oil

Cancer therapy

Cancer Mycoplasma

Cancer Regan

Green tea  and cancer risk

Beet Root  anti cancer

Curry Powder

Sulphur Bath

Water chestnut 

Sweet potatoes  vitamin

Magnet therapy

Magnet Deficiency

Magnetic environment

Electronic stimulation

Electronic cures


Axonal  Polyneuropathy changes in EMG 

EMG/NCV section Learn about the Brain

Learn about nerves

Want to learn about nerve p











        Jonathan Katz MD on nerve Biopsy
    Natural treatments for diseases see this link  

              October 12, 2004

Please click the +1 button if you like this page Thanks

The Orange County Neurological Society For Education and Service to our   Community



 Jonathan S.Katz, MD

Department of Neurology

Stanford University

Chronic Immune Neuropathies:  IVIG as treatment and diagnostic test


  Here is a review of what Dr. Katz had to say. He told the neurologist attending this meeting that we should stop worrying about the cost of the treatments; there is always the H.M.O. to take care of this issue. So let the HMO worry who can get IVIg .

Following tests for neuropathy are not needed, (antibody screens, neuropathy panels) the cost of these screens varies from 1500 to 2000 dollars and then one does not know what to do with the result. Sedimentation rate should be done along with a B12 level as you can diagnose vasculitis or vitamin deficiency based upon the results.

   No nerve biopsy should  be attempted; this will leave the patient with a life long sensory deficit (Do Not Cause Any Harm) Hippocraties. Biopsy is useless in patients with CIDP as they have skip lesions, which cannot be seen on a routine biopsy. Some patients have motor involvement and the sural biopsy will not show this. Because sural nerve is a pure sensory nerve. The diagnois should be based upon clinical examination.

    Finally do not follow any guidelines to make a diagnosis. As only 20-30% of the patients will fit the AAN guideline. Patients will come in with different presentations.

   EMG/NCV can be normal if only small fibers are involved, or show axonal or demyelinating pattern. Thus you cannot depend upon the EMG/NCV to diagnose CIDP.

 So the best test to prove that patient has a immune neuropathy is to treat them with IVIG.

Those that report improvement should be considered as suffering from immune neuropathies.

Usually you will not see a improvement in their examination after they have been treated with a course of IVIg. If the patient states that they have been helped then its best to document this. 

Steroids will not improve axonal conditions like M.M.N. They may help CIDP patients but will take 2-3 months to see a response.

Dr Katz has published several papers on CIDP and he wrote the Medicare guidelines for CIDP in California.

 Read about axonal EMG findings in CIDP

Axonal multifocal motor neuropathy without conduction block or other features of demyelination

J.S. Katz, MD;, R.J. Barohn, MD;, S. Kojan, MD;, G.I. Wolfe, MD;, S.P. Nations, MD;, D.S. Saperstein, MD; and A.A. Amato, MD

From the Departments of Neurology, Palo Alto VA Medical Center and Stanford University (Dr. Katz), Palo Alto, CA; University of Kansas Medical Center (Dr. Barohn), Kansas City; University of Texas Southwestern Medical Center (Drs. Kojan, Wolfe, Nations, and Saperstein), Dallas; and Brigham and Women’s Hospital (Dr. Amato), Harvard Medical School, Boston, MA.

Address correspondence and reprint requests to Dr. Jonathan Katz, Department of Neurology (127), Department of Veterans Affairs, 3801 Miranda Ave., Palo Alto, CA 94304; e-mail: jskatz@stanford.edu

Background: Conduction block is considered an essential finding for the distinction between motor neuropathies and lower motor neuron disorders. Only a small number of reports describe patients with multifocal motor neuropathies who lack overt conduction block, although in these cases other features of demyelination still suggest the presence of a demyelinating disorder. In contrast, a purely axonal multifocal motor neuropathy has not been described.

Methods: This report describes nine patients with slowly or nonprogressive multifocal motor neuropathies who had purely axonal electrodiagnostic features.

Results: GM1 antibodies titers were normal in all nine cases. Six patients were treated with either prednisone or IV immunoglobulin and three showed convincing improvement.

Conclusions: These findings suggest an immune-mediated motor neuropathy with axonal electrophysiologic features that appears to be distinct from both multifocal motor neuropathy and established motor neuron disorders.


                     Rheumatoid story